Table 4.

Treatment‐emergent adverse events

Adverse events, n (%)	Neratinib a (n = 15)	Lansoprazole b (n = 15)	Neratinib + Lansoprazole c (n = 15)	Total (n = 15)
Subjects with adverse events	4 (27)	1 (7)	2 (13)	5 (33)
Diarrhoea	1 (7)	0	2 (13)	3 (20)
Flatulence	2 (13)	0	0	2 (13)
Abdominal pain	1 (7)	0	0	1 (7)
Fatigue	1 (7)	0	0	1 (7)
Dizziness	0	1 (7)	0	1 (7)
Headache	1 (7)	0	0	1 (7)

Note: all events were mild

^a Postdose on Day 1/Period 1 to predose on Day 1/Period 2

^b Postdose on Day 1/Period 2 to predose neratinib on Day 5/Period 2

^c Postdose neratinib on Day 5/Period 2 to end of study